偏头痛预防药物致体重增加与下丘脑神经肽的关系

THE RELATIONSHIP BETWEEN HYPOTHALAMIC PEPTIDES AND WEIGHT GAIN INDUCED BY MIGRAINE PREVENTIVE DRUGS

目的：探讨偏头痛预防药物致体重增加与下丘脑神经肽的关系.方法：选择104例体重指数＜25 kg/m2且无内分泌和代谢性疾病的偏头痛患者,随机分成两组,分别用阿米替林或氟桂利嗪预防治疗6个月.采用放射免疫测定法测定各组患者在治疗前及治疗后第2、4、6个月时Orexin A、Orexin B和神经肽Y的血浆浓度.结果：两组患者经药物预防治疗后血浆中Orexin A和Orexin B浓度明显减少,而神经肽Y浓度却明显增加.OrexinA、OrexinB浓度减少与体重增加呈负相关,而神经肽Y浓度增加与体重增加呈正相关.结论：偏头痛患者用阿米替林或氟桂利嗪预防治疗后体重增加可能与下丘脑神经肽相关.

Objective：To investigate the relationship between hypothalamie neuropeptides and weight gain induced by migraine preventive drugs.Methods：One hundred and four migraine patients with body mass index ＜25 kg/m2 without endocrinological or metabolic diseases were randomized into two treatment groups,one receiving amitriptyline,the other flunarizine,for 6 months.The plasma levels of Orexin A,Orexin B and neuropeptide Y were measured with radioimmunoassay at baseline and the 2nd,4th,6th months of preventive treatment.Results：The levels of Orexin A and Orexin B were significantly reduced whereas the levels of neuropeptide Y markedly increased in both groups.The weight gain were negatively correlated to the levels of Orexin A and Orexin B and positively correlated to the levels of neuropeptide Y in both groups during the treatment period.Conclusion：The changes in the levels of hypothalamic peptides may contribute to body weight gain occurring in migraineurs during amitriptyline or flunarizine prophylactic treatment.